Insider Selling: Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells 37,524 Shares of Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 37,524 shares of Eton Pharmaceuticals stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $31.49, for a total transaction of $1,181,630.76. Following the completion of the sale, the insider owned 25,249 shares of the company’s stock, valued at approximately $795,091.01. The trade was a 59.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

David Krempa also recently made the following trade(s):

• On Friday, May 22nd, David Krempa sold 42,797 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $33.39, for a total transaction of $1,428,991.83.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON traded up $1.11 during midday trading on Wednesday, reaching $32.40. The company’s stock had a trading volume of 442,334 shares, compared to its average volume of 358,595. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21. Eton Pharmaceuticals, Inc. has a fifty-two week low of $13.09 and a fifty-two week high of $35.66. The business’s 50 day moving average price is $26.33 and its two-hundred day moving average price is $19.94. The company has a market cap of $887.50 million, a P/E ratio of -462.79 and a beta of 0.82.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The business had revenue of $24.27 million during the quarter, compared to analyst estimates of $22.31 million. On average, analysts forecast that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ETON. Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Zacks Research downgraded shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th. HC Wainwright boosted their price objective on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, May 15th. B. Riley Financial boosted their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $41.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ETON. Millennium Management LLC increased its holdings in shares of Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after buying an additional 217,042 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock worth $2,274,000 after buying an additional 45,341 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Eton Pharmaceuticals by 49.1% during the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock worth $1,245,000 after buying an additional 31,596 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Eton Pharmaceuticals by 114.5% during the second quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company’s stock worth $3,457,000 after buying an additional 129,467 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Eton Pharmaceuticals during the second quarter worth $41,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.